Opioid Use Disorder (OUD) Market: Orexo AB Signs Agreement with GAIA AG to Develop a Novel Digital Therapy (DTx) for Treating OUD, reports Fortune Business Insights™

The global opioid use disorder (OUD) market is set to gain traction from the surging adoption of buprenorphine treatment patches for treating opioid addiction. It is considered to be an effective therapy. Several companies are also engaging in the collaboration strategy to develop new products. For instance, Orexo AB joined hands with Magellan Rx Management and ApexB.io in February 2021 to conduct research on the usage of a digital therapeutic named modia. It is best suited for people living with OUD. Fortune Business Insights™ published this information in its latest report, titled, “Opioid Use Disorder (OUD) Market, 2021-2028.” The report further states that this market is projected to grow from USD 2.68 billion in 2021 to USD 4.81 billion in 2028 at a CAGR of 8.7% in the forthcoming years. It stood at USD 2.52 billion in 2020.

Request a Sample Copy of the Research Report:

https://www.fortunebusinessinsights.com/enquiry/sample/opioid-use-disorder-oud-market-102674

COVID-19 Pandemic: Cancellation of Patient Visits to Hamper Growth

The COVID-19 pandemic has had a mixed impact on the pharmaceutical market. Some of the medicines have showcased a decline in their demand because of the reduced patient visits in clinics and hospitals. Also, the postponement or cancellation of doctor appointments has severely affected the market. But, the number of people suffering from opioid relapses and overdoses has surged rapidly amid the pandemic, which, in turn, is set to aid growth. Our research reports would help you better understand the current scenario of the OUD industry.

Quick Buy

https://www.fortunebusinessinsights.com/checkout-page/102674

SEGMENTATION

Buprenorphine Segment Held 81.5% Share in 2020: Fortune Business Insights™

Based on the route of administration, the market for opioid use disorder is segregated into oral and parenteral. By the distribution channel, it is divided into hospital pharmacies, retail pharmacies & stores, and online pharmacies. Lastly, based on the drug class, it is trifurcated into buprenorphine, methadone, and naltrexone. Out of these, the buprenorphine segment held 81.5% in terms of the opioid use disorder market share in 2020. This growth is attributable to the rising usage of these drugs in developed markets, such as France and the U.S.

Report Coverage-

Our skilled research analysts have presented an accurate picture of the opioid use disorder industry by summation, synthesis, and study of data from various significant sources. They have also included multiple facets of the industry with the main focus on determining the significant market influencers. Thus, the data is reliable and comprehensive. It was gathered by conducting extensive primary and secondary research.

Have Any Query? Ask Our Experts:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/opioid-use-disorder-oud-market-102674

DRIVING & RESTRAINING FACTORS

Rising Prevalence of Cancer, Injuries, and Cardiovascular Disorders to Aid Growth

The general population nowadays suffers from a wide range of chronic and severe health conditions, such as pain arising from injuries or cancer. They often result in chronic pain and in such cases, patients are given painkillers, especially opioids. While they help in lowering pain, they can cause addiction among patients. The abrupt discontinuation or higher dependency on these drugs leads to withdrawal symptoms. This further increases the chances of fatal consequences, such as deaths.

The American Psychiatric Association (APA), for instance, mentioned that approximately 72,000 Americans died due to drug overdose in 2017. These factors are likely to drive the opioid use disorder market growth in the near future. However, the drugs used for the treatment of opioid addiction can have various side-effects, such as bone/joint pain, abdominal cramps, constipation, respiratory issues, and vomiting. It may obstruct their demand.

REGIONAL INSIGHTS

Presence of Multiple Renowned Companies to Help North America Dominate

North America procured USD 1.95 billion in 2020 in terms of revenue. It is set to remain at the forefront because of the presence of reputed companies in the region. At the same time, the surging government initiatives for tackling the rising opioid dependency would augment the market for opioid use disorder in the forthcoming years. Europe, on the other hand, is expected to remain in the second position attributable to the increasing cases of opioid dependency and the rising number of advanced product launches in the region.

COMPETITIVE LANDSCAPE

Key Companies Aim on Collaborations and Partnerships to Gain a Competitive Edge

This market is experiencing a healthy competition between various prominent organizations that are striving persistently to compete with their rivals. Most of them are engaging in the partnership strategy with other companies to broaden their pre-existing product portfolios. A few others are signing new agreements with local firms to develop new treatment options. Below is one of the latest industry developments:

Industry Development:

August 2019: Orexo AB signed an agreement with GAIA AG to develop a novel digital therapy (DTx) for treating OUD. The product is likely to be launched in 2021. Orexo aims to enhance the existing treatment plans and provide access to patients.
A List of Key Companies Operating in this Market:

Indivior PLC (Chesterfield, U.S.)
Alkermes (Dublin, Ireland)
Orexo AB (Uppsala, Sweden)
Titan Pharmaceuticals, Inc. (South San Francisco, U.S.)
Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)
Mallinckrodt Pharmaceuticals (Staines-Upon-Thames, U.K.)
BioDelivery Sciences International Inc. (Raleigh, U.S.)
Viatris Inc. (Mylan N.V.) (Canonsburg, U.S.)
Pfizer, Inc. (New York City, U.S.)
Hikma Pharmaceuticals PLC (London, U.K.)
Camurus (Lund, Sweden)
Other Players
Table Of Content

Introduction
Research Scope
Market Segmentation
Research Methodology
Definitions and Assumptions
Executive Summary
Market Dynamics
Market Drivers
Market Restraints
Market Opportunities
Key Insights
Pipeline Analysis
New Product Launches
Statistics of Opioid Use Disorder
Industry Developments Such as Mergers, Acquisitions, and Collaborations
Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2017-2028
Key Findings / Summary
Market Analysis, Insights and Forecast – By Drug Class
Buprenorphine
Methadone
Naltrexone
Market Analysis, Insights and Forecast – By Route of Administration
Oral
Parenteral
Market Analysis, Insights and Forecast – By Distribution Channel
Hospitals Pharmacies
Retail Pharmacies & Stores
Online Pharmacies
Market Analysis, Insights and Forecast – By Region
North America
Europe
Asia Pacific
Rest of the World
ToC continue…!

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email:sales@fortunebusinessinsights.com

This release was published on openPR.